60 Degrees Pharmaceuticals (SXTP) Non-Current Debt (2022 - 2025)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Non-Current Debt of $144003.0 for Q4 2025, down 2.12% year-over-year from $147119.0 in Q4 2024, and down 2.12% quarter-over-quarter from $147119.0 in Q4 2024.
60 Degrees Pharmaceuticals (SXTP) Non-Current Debt (2022 - 2025) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Non-Current Debt for 4 consecutive years, with $144003.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Debt fell 2.12% year-over-year to $144003.0; the TTM figure through Dec 2025 stood at $144003.0 (down 2.12% YoY), while the FY2025 annual figure was $144003.0, down 2.12% from the prior year.
- Non-Current Debt eased to $144003.0 in Q4 2025 per SXTP's latest filing, from $147119.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $2.2 million in Q3 2023 and bottomed at $144003.0 in Q4 2025.
- Historically, Non-Current Debt has averaged $959050.8 across 4 years, with a median of $1.1 million in 2022.
- On a YoY basis, Non-Current Debt climbed as much as 2.12% in 2025 and fell as far as 2.12% in 2025.
- 60 Degrees Pharmaceuticals' Non-Current Debt stood at $1.1 million in 2022, then surged by 95.91% to $2.2 million in 2023, then sank by 93.23% to $147119.0 in 2024, then dropped by 2.12% to $144003.0 in 2025.
- Business Quant data shows SXTP's Non-Current Debt at $144003.0 in Q4 2025, $147119.0 in Q4 2024, and $2.2 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 144,003.00 |
| Dec 31, 2024 | 147,119.00 |
| Sep 30, 2023 | 2.17 Mn |
| Jun 30, 2023 | 1.22 Mn |
| Dec 31, 2022 | 1.11 Mn |